Samil Pharmaceutical signs co-sales agreement of ‘Lastacaft Soln’ with Allergan

Published: 2018-05-17 15:20:20

Updated: 2018-05-17 15:20:20

Samil Pharmaceutical(CEO Seung-Beom Huh) announced on 14 Mary that the company signed a distribution and co-sales agreement of Lastacaft Ophthalmic Solution 0.25% 5mL(alcaftadine), an allergic conjunctivitis therapy, with Allergan Korea(CEO Eun-Young Kim).

Thus, Samil Pharmaceutical has taken over the Korean distribution license of Lastacaft from 14 May, and will take joint promotional activit...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.